Navigation Links
OncoGenex Reports Third Quarter 2009 Financial Results
Date:11/5/2009

Conference Call on Thursday, November 5, 2009 at 4:30 p.m. Eastern Time

BOTHELL, WA and VANCOUVER Nov. 5 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ("OncoGenex" or the "Company") (NASDAQ: OGXI) today reported unaudited financial results for the third quarter and nine months ended September 30, 2009 and reviewed the Company's highlights for the third quarter of 2009.

The following consolidated results reflect the operations of OncoGenex Technologies Inc. ("OncoGenex Technologies") prior to the August 21, 2008 reverse takeover of Sonus Pharmaceuticals, Inc. ("Sonus"), and the consolidated results of OncoGenex thereafter.

Research and development expenses for the third quarter of 2009 decreased to $1.5 million from $1.6 million in 2008, due mainly to lower costs associated with OGX-427. For the nine months ended September 30, 2009 research and development expenses increased to $6.8 million from $3.6 million in 2008. The increase was primarily due to OGX-011 and OGX-427 manufacturing-related costs incurred in the first nine months of 2009, an increase in employee expenses and higher facility costs resulting from the reverse takeover of Sonus. Reducing the expenses in the first nine months of 2008 was a Scientific Research and Development (SRED) claim, which offset R&D expenses in that period. The SRED program is a Canadian federal tax incentive program that encourages Canadian businesses to conduct research and development in Canada. As OncoGenex Technologies became an affiliate of a public company as a result of the reverse takeover, SRED claims can now only be applied against taxes payable.

General and administrative expenses for the third quarter decreased to $0.9 million from $1.0 million in 2008, due mainly to lower legal and accounting fees incurred in 2009. For the nine months ended S
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... Warren, NJ (PRWEB) , ... September 01, 2015 , ... ... paper that highlights the opportunities for advanced analytics utilizing data lakes in the ... all industries, Healthcare has seen an explosion of data over the last few years ...
(Date:9/1/2015)... ... September 01, 2015 , ... Research conducted by Synedgen ... Boston University School of Medicine, Frederick National Laboratory for Cancer Research, and the ... multidisciplinary Open Access journal. , Christopher Ryan PhD, of Synedgen, and Aparajita ...
(Date:8/31/2015)... BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... emission abatement projects in North America . ... a municipality in the Southern USA ... failed to meet the customer,s requirements. This demonstrates the value our ... Webb , President and Chief Executive Officer.  ...
(Date:8/31/2015)... DUBLIN , Aug. 31, 2015 Research ... of the "Mexico Biomedical Sensors Market - Growth, ... The Mexico Biomedical Sensors market ... CAGR of 2.68% over the period 2014-2020 ... adaptable to the genetic formulation of each individual. These ...
Breaking Biology Technology:New White Paper Explores Data Lake Opportunities in the Healthcare Industry 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 3Mexico Biomedical Sensors Market Report 2015-2020 2
... Inc. announced today that it has been awarded funding ... pre-clinical research targeting alpha-synuclein, a protein whose clumping is ... NeuroPhage,s first grant from MJFF. "It ... development of our novel therapeutic approach.  This grant will ...
... ARBOR, Mich., Feb. 16, 2012  Adeona Pharmaceuticals, Inc. (NYSE ... DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, ... of stockholders to change its corporate name to Synthetic ... will start trading under its new name and stock ...
... February 15, 2012 CitiusTech, a leading ... the calendar year 2011 with 59% growth in revenues. ... has recorded over 50% Y-o-Y revenue growth. In 2011, ... healthcare technology. CitiusTech was selected as a finalist at ...
Cached Biology Technology:NeuroPhage Receives Michael J. Fox Foundation Funding for Parkinson's Disease Research 2CitiusTech Completes Another Milestone Year: Revenues Grow by 59% in 2011 2
(Date:8/25/2015)... SALT LAKE CITY and BELLEVUE, ... a global leader in advanced robotic systems, announced today ... first-of-its-kind robotic unmanned ground vehicle (UGV), at the National ... Lake City.  The Guardian S is ... is the culmination of years of research and in-field ...
(Date:8/20/2015)... 2015   Sensory, Inc ., a Silicon ... experience and security of consumer electronics through state-of-the-art ... its TrulySecure™ is the first multimodal ... FIDO Certified™. The FIDO (Fast Identification ... FIDO UAF (Universal Authentication Framework) 1.0 specifications, which ...
(Date:8/18/2015)... 17, 2015 Research and Markets ( ... "Global Biometric Authentication & Identification Market: Focus ... Forecast, 2015-2020" report to their offering. ... systems market is expected to grow at an ... and generate over $25 billion (approximately) by 2020 ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... Scientists have identified a genetic variation in people ... muscle cells respond to the hormone insulin, in a ... The researchers, from Imperial College London and other international ... scientists developing treatments for diabetes. Previous studies have ...
... to restore to normal levels a key protein involved ... have been shown to cause the rare brain disorder ... mental retardation and very early death in human infants. ... mice, that the genetic equivalent to human lissencephaly, also ...
... what you know often comes at the price of learning ... easy for many, but not for those with conditions such ... simple routines. Using brain scans in monkeys, Duke ... monkeys will switch from exploiting a known resource to exploring ...
Cached Biology News:Scientists discover new genetic variation that contributes to diabetes 2Researchers restore missing protein in rare genetic brain disorder 2Researchers restore missing protein in rare genetic brain disorder 3Monkey brains signal the desire to explore 2
... Timp-4 has been reported in heart ... fibroblasts in cell culture conditions. ... TPA stimulates production of TIMP-4 in ... protein levels produced often require concentration ...
Goat polyclonal to HSPC150 ( Abpromise for all tested applications). entrezGeneID: 29089...
Anti-MMP-13 Collagenase-3, amino terminal end of active enzyme; rabbit host...
...
Biology Products: